Repatha Appetite & Cravings Changes: What the Evidence Actually Shows

Does Repatha change appetite or food cravings?

Appetite changes are not listed in the label's reported adverse-reaction data [1]. That does not rule out an appetite change in an individual.

Evolocumab is a human monoclonal IgG2 antibody that binds PCSK9, a protein that normally attaches to the LDL receptor on liver cells and drives its degradation [1]. Blocking that interaction leaves more LDL receptors available to pull LDL cholesterol out of the blood [1]. The label describes this action on cholesterol clearance and does not describe a hunger or satiety effect [1].

What the label's trials actually recorded

The label's main adverse reaction table comes from a 52-week placebo-controlled trial of 599 adults on evolocumab 420 mg monthly and 302 on placebo [1]. Reactions reported more often with evolocumab than placebo were:

• Nasopharyngitis: 10.5% vs 9.6% [1]
• Upper respiratory tract infection: 9.3% vs 6.3% [1]
• Influenza: 7.5% vs 6.3% [1]
• Back pain: 6.2% vs 5.6% [1]
• Injection site reactions: 5.7% vs 5.0% [1]
• Cough: 4.5% vs 3.6% [1]
• Urinary tract infection: 4.5% vs 3.6% [1]
• Sinusitis: 4.2% vs 3.0% [1]
• Headache: 4.0% vs 3.6% [1]
• Myalgia: 4.0% vs 3.0% [1]
• Dizziness: 3.7% vs 2.6% [1]

Discontinuation because of an adverse reaction was 2.2% on evolocumab vs 1.0% on placebo, and myalgia was the most common reason (0.3% vs 0%) [1].

Across eight pooled controlled trials, injection site reactions were 3.2% vs 3.0% on placebo (mostly erythema, pain and bruising, with 0.1% discontinuing) and hypersensitivity reactions were 5.1% vs 4.7%, including rash 1.0% vs 0.5% and urticaria 0.4% vs 0.1% [1]. The label's post-marketing list adds angioedema and influenza-like illness [1]. None of these lists includes appetite loss, increased appetite, food cravings or hyperphagia.

Did any large trial measure appetite or hunger?

The large Repatha trials focused on cardiovascular events and cognition. FOURIER (27,564 adults with atherosclerotic cardiovascular disease on statins) and VESALIUS-CV (12,257 adults with atherosclerosis or diabetes and no previous heart attack or stroke) were designed to count cardiovascular events [2][3]. The EBBINGHAUS substudy of FOURIER tested cognition; evolocumab was non-inferior to placebo on the spatial working memory strategy index of executive function over a median of 19 months [4]. The label adds that it was also non-inferior on selected other cognitive domains [1].

No identified study measured appetite or food intake in people taking evolocumab.

Does the way the drug works point to an appetite effect?

Not from the labeled pharmacology. After a single subcutaneous dose, unbound PCSK9 was maximally suppressed within 4 hours, and the largest LDL cholesterol reduction arrived by 2 weeks after a 140 mg dose and by 3 weeks after 420 mg [1]. The label has no drug interactions section [1].

What the label does warn about

Repatha carries no boxed warning. Its only Warning and Precaution is for hypersensitivity reactions including angioedema; the label says to stop treatment and treat the reaction if serious symptoms occur [1]. A history of a serious hypersensitivity reaction to evolocumab or any ingredient is a contraindication [1].

The needle cover on some autoinjector and syringe presentations contains dry natural rubber, which can cause reactions in people sensitive to latex; latex-free presentations exist [1]. The label describes a 420 mg dose as three consecutive 140 mg injections within 30 minutes [1].

If appetite changes while taking Repatha

The label does not establish whether an individual appetite change is related to Repatha [1].

What the label does document is what was reported in its trials: upper respiratory and flu-like symptoms, back and muscle pain, headache, dizziness and injection site reactions [1].